title: Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
authors.affiliation: Department of Neurology and Stroke Center, University Duisburg-Essen, Essen, Germany. hans.diener@uni-duisburg-essen.de
authors.forename: H C
authors.initials: HC
authors.lastname: Diener
authors.forename: R
authors.initials: R
authors.lastname: Weber
authors.forename: C
authors.initials: C
authors.lastname: Weimar
authors.forename: J
authors.initials: J
authors.lastname: Röther
mesh_terms: D000077284:Abciximab; D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002908:Chronic Disease; D000077144:Clopidogrel; D003692:Delayed-Action Preparations; D004176:Dipyridamole / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D002546:Ischemic Attack, Transient / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D020521:Stroke / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin; D000077284:Abciximab